All In Biotech

Drug Trial Radar · NCT00724789

Monitor the Incidence of Congenital Malformations in Infants of Women Who Have Been Treated With Ganirelix (Orgalutran®)(Study 38644)(P05966)(COMPLETED)

An Open-label, Observational Trial to Monitor the Incidence of Congenital Malformations in Infants of Women With an Ongoing Pregnancy After Controlled Ovarian Hyperstimulation Using Puregon® (recFSH)/Orgalutran® (Ganirelix) Followed by IVF/ICSI, or a Long Protocol With a GnRH Agonist as Historical Controls.

Last checked: Nov 20, 2026Latest source record: Feb 3, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

2,066

Actual

Start

Nov 2000

Primary completion

Nov 2005

Study completion Nov 2005

Sponsor

Lead sponsor
Organon and CoIndustry
Sponsor type
Industry
First posted
Jul 30, 2008

More drug trials from this sponsor

Design

Study type
Observational
Who can join
Female only, from 18 years, up to 39 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to collect data on the incidence of congenital malformations in infants of women with an ongoing pregnancy after controlled ovarian stimulation with recombinant follicle stimulating hormone /ganirelix followed by in vitro fertilization (IVF) or intra cytoplasmatic sperm injection (ICSI), and to compare this incidence with that of a group of women who used a long protocol with a gonadotropin releasing hormone agonist as historical controls.

Conditions

  • Pregnancy
  • Neonates

Interventions

  • ganirelixDrug

    Daily 0.25 mg ganirelix administered to prevent premature LH surges during COS in order to achieve a pregnancy

  • GnRH agonistDrug

    Long protocol of GnRH agonist administered to prevent premature LH surges during COS in order to achieve a pregnancy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To collect data on the incidence of congenital malformations in infants of women with an ongoing pregnancy after controlled ovarian hyperstimulation.Time frame: In both cohorts a follow-up pediatric evaluation was scheduled within 6 months post-partum

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.